

BC #7
PCT09

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/787,356

DATE: 07/24/2001

TIME: 13:36:53

Input Set : A:\DAVI122.001APC.TXT

Output Set: N:\CRF3\07242001\I787356.raw

ENTERED

4 <110> APPLICANT: Cocks, Thomas Mathew
 5 Moffat, James David
 7 <120> TITLE OF INVENTION: A METHOD OF TREATMENT AND AGENTS USEFUL
 8 FOR SAME
 10 <130> FILE REFERENCE: DAVI122.001APC
 12 <140> CURRENT APPLICATION NUMBER: US 09/787,356
 13 <141> CURRENT FILING DATE: 2001-03-15
 15 <150> PRIOR APPLICATION NUMBER: PCT/AU99/00775
 16 <151> PRIOR FILING DATE: 1999-09-15
 18 <150> PRIOR APPLICATION NUMBER: AU/PP5922
 19 <151> PRIOR FILING DATE: 1998-09-15
 21 <150> PRIOR APPLICATION NUMBER: AU/PP8658
 22 <151> PRIOR FILING DATE: 1999-02-12
 24 <160> NUMBER OF SEQ ID NOS: 8
 26 <170> SOFTWARE: FastSEQ for Windows Version 4.0
 28 <210> SEQ ID NO: 1
 29 <211> LENGTH: 6
 30 <212> TYPE: PRT
 31 <213> ORGANISM: Artificial Sequence
 33 <220> FEATURE:
 34 <223> OTHER INFORMATION: The peptide TRAP from human protease-activated
 35 receptor 1 (PAR-1).
 37 <400> SEQUENCE: 1
 38 Ser Phe Leu Leu Arg Asn
 39 1 5
 42 <210> SEQ ID NO: 2
 43 <211> LENGTH: 6
 44 <212> TYPE: PRT
 45 <213> ORGANISM: Artificial Sequence
 47 <220> FEATURE:
 48 <223> OTHER INFORMATION: The peptide PAR2-AP from human protease-activated
 49 receptor 2 (PAR-2).
 51 <400> SEQUENCE: 2
 52 Ser Leu Ile Gly Arg Leu
 53 1 5
 56 <210> SEQ ID NO: 3
 57 <211> LENGTH: 6
 58 <212> TYPE: PRT
 59 <213> ORGANISM: Artificial Sequence
 61 <220> FEATURE:
 62 <223> OTHER INFORMATION: The human protease-activated receptor 2 (PAR-2)
 63 tethered ligand sequence
 65 <400> SEQUENCE: 3
 66 Ser Leu Ile Gly Lys Val
 67 1 5
 70 <210> SEQ ID NO: 4
 71 <211> LENGTH: 6

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/787,356

DATE: 07/24/2001

TIME: 13:36:53

Input Set : A:\DAVI122.001APC.TXT

Output Set: N:\CRF3\07242001\I787356.raw

```

72 <212> TYPE: PRT
73 <213> ORGANISM: Artificial Sequence
75 <220> FEATURE:
76 <223> OTHER INFORMATION: Scrambled peptide sequence
78 <400> SEQUENCE: 4
79 Leu Ser Ile Gly Arg Leu
80 1 5
83 <210> SEQ ID NO: 5
84 <211> LENGTH: 7
85 <212> TYPE: PRT
86 <213> ORGANISM: Artificial Sequence
88 <220> FEATURE:
89 <223> OTHER INFORMATION: The carboxyl-terminal of mouse protease-activated
90 receptor 2 (PAR2)
92 <400> SEQUENCE: 5
93 Cys Ser Val Lys Thr Ser Tyr
94 1 5
97 <210> SEQ ID NO: 6
98 <211> LENGTH: 6
99 <212> TYPE: PRT
100 <213> ORGANISM: Artificial Sequence
102 <220> FEATURE:
103 <223> OTHER INFORMATION: The protease-activated receptor 4 (PAR-4)
104 activating peptide
106 <400> SEQUENCE: 6
107 Gly Tyr Pro Gly Lys Phe
108 1 5
111 <210> SEQ ID NO: 7
112 <211> LENGTH: 7
113 <212> TYPE: PRT
114 <213> ORGANISM: Artificial Sequence
116 <220> FEATURE:
117 <223> OTHER INFORMATION: The human protease-activated receptor 2 (PAR-2)
118 tethered ligand sequence
120 <400> SEQUENCE: 7
121 Ser Leu Ile Gly Lys Val Asp
122 1 5
125 <210> SEQ ID NO: 8
126 <211> LENGTH: 6
127 <212> TYPE: PRT
128 <213> ORGANISM: Artificial Sequence
130 <220> FEATURE:
131 <223> OTHER INFORMATION: The protease-activated receptor 4 (PAR-4)
132 activating peptide
134 <400> SEQUENCE: 8
135 Gly Tyr Pro Gly Gln Tyr
136 1 5

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/787,356

DATE: 07/24/2001

TIME: 13:36:54

Input Set : A:\DAVI122.001APC.TXT

Output Set: N:\CRF3\07242001\I787356.raw